UBS Downgrades Humana to Neutral, Lowers Price Target to $370
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo downgraded Humana (NYSE:HUM) from Buy to Neutral and reduced the price target from $530 to $370, indicating a more cautious outlook on the company's stock.
January 26, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Humana's downgrade from Buy to Neutral by UBS and a significant reduction in price target could lead to a negative investor sentiment and a potential decrease in stock price in the short term.
Analyst downgrades typically lead to a negative short-term reaction in the stock market as they suggest a less favorable outlook on the company's future performance. The substantial decrease in the price target from $530 to $370 by a major financial institution like UBS is likely to be taken seriously by investors, potentially leading to a sell-off.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100